论文部分内容阅读
目的:探讨黄芪颗粒在预防过敏性紫癜(HSP)患儿肾损害中的作用。方法:将96例HSP患儿随机分成治疗组48例和对照组48例,两组均予以维生素C、西咪替丁、芦丁片、葡萄糖酸钙和低分子肝素钠等综合治疗,治疗组在此基础上加用口服黄芪颗粒3个月。对两组患儿随访6个月,观察两组患儿症状消退时间,动态监测两组患儿尿常规、尿m-Alb和尿NAG酶的变化,分析两组患儿肾损害发生时间和发生率。结果:治疗后治疗组患儿症状消退时间明显短于对照组,两组比较差异有统计学意义(P<0.05);随访6个月,不同时间点治疗组患儿尿常规异常例数少于对照组,差异均有统计学意义(P<0.05);不同时间点治疗组患儿尿m-Alb和尿NAG酶水平低于对照组,差异有统计学意义(P<0.05);治疗组肾损害发生时间晚于对照组,发生率低于对照组,差异均有统计学意义(P<0.05)。结论:黄芪颗粒治疗HSP,能降低肾损害的发生率,改善HSP的预后,具有积极的临床意义。
Objective: To investigate the role of astragalus in the prevention of renal damage in children with Henoch-Schonlein purpura (HSP). Methods: 96 children with HSP were randomly divided into treatment group (n = 48) and control group (n = 48). The two groups were treated with vitamin C, cimetidine, rutin tablet, calcium gluconate and low molecular weight heparin. On this basis plus oral administration of Astragalus particles for 3 months. The patients in both groups were followed up for 6 months. The symptom subsided time was observed in both groups. The urinary routine, urine m-Alb and urinary NAG were dynamically monitored in both groups. The time and occurrence of renal damage in both groups were analyzed rate. Results: After treatment, the symptoms of children in the treatment group were significantly shorter than those in the control group (P <0.05). After 6 months of follow-up, the number of abnormal urination in the treatment group was less than (P <0.05). The levels of urinary m-Alb and urine NAG in the treatment group were lower than those in the control group at different time points, the difference was statistically significant (P <0.05). The treatment group The incidence of injury later than the control group, the incidence was lower than the control group, the difference was statistically significant (P <0.05). Conclusion: Astragalus membranaceus treatment of HSP, can reduce the incidence of renal damage and improve the prognosis of HSP, with a positive clinical significance.